Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEDILANID-D vs CINACALCET HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.
Allosteric activator of the calcium-sensing receptor (Ca SR) on parathyroid chief cells, increasing sensitivity to extracellular calcium and reducing parathyroid hormone (PTH) secretion.
Heart failure,Atrial fibrillation,Atrial flutter
Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis,Hypercalcemia in patients with parathyroid carcinoma,Severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy
0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.
30 mg orally once daily, titrate every 2-4 weeks to a maximum of 180 mg once daily to achieve target intact parathyroid hormone (i PTH) level.
Terminal elimination half-life is 36-48 hours in patients with normal renal function; prolonged to >100 hours in severe renal impairment, requiring dose adjustment.
Terminal elimination half-life: 30–40 hours in patients with normal renal function; prolonged to 42–83 hours in moderate to severe hepatic impairment. Steady-state reached within 7 days.
Hepatic (minor); primarily renally excreted unchanged.
Hepatic via CYP3A4, CYP2D6, and CYP1A2; major metabolites are inactive.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 30-40%, with enterohepatic circulation present.
Renal: 80% (as metabolites), Fecal: 15%, Biliary: negligible.
25-30% bound to plasma albumin.
97% bound to albumin.
6-10 L/kg; large Vd indicates extensive tissue distribution and high cardiac tissue affinity.
Approximately 1.7 L/kg (1000 L for 70 kg person), indicating extensive tissue distribution.
Oral: 70-80%; IV: 100%.
76–82% (oral); food increases AUC by 50–80%.
GFR <50 m L/min: reduce dose by 50% or extend dosing interval to every 36-48 hours. GFR <10 m L/min: avoid use or reduce dose by 75%.
No dose adjustment required for any degree of renal impairment, including end-stage renal disease (ESRD) on dialysis.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: avoid use or reduce dose by 75%.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate to severe hepatic impairment (Child-Pugh B or C): reduce starting dose to 30 mg daily and monitor i PTH and serum calcium closely.
Digitalizing dose: 0.01-0.02 mg/kg IV or IM, given in divided doses over 24 hours. Maintenance: 10-20% of digitalizing dose daily. Not recommended for neonates due to prolonged half-life.
Not established for pediatric patients; safety and efficacy in children have not been determined.
Reduce dose by 25-50% due to decreased renal function and increased sensitivity. Monitor serum levels and renal function closely.
No specific dose adjustment recommended; clinical studies included patients aged 65 and older, but no overall differences in safety or efficacy were observed. Use with caution due to potential for increased sensitivity.
Can cause potentially fatal arrhythmias; use only when clearly indicated and monitor serum levels.
None.
Narrow therapeutic index; toxicity risk increased with hypokalemia, hypomagnesemia, hypercalcemia, renal impairment; monitor ECG and drug levels.
Hypocalcemia: Can cause life-threatening hypocalcemia; monitor serum calcium levels frequently.,Seizures: Increased risk, especially in patients with history of seizure disorder.,QT interval prolongation: Hypocalcemia may exacerbate QT prolongation; monitor ECGs in patients with risk factors.,Hypotension and worsening heart failure: Cases reported, especially in patients with impaired cardiac function.,Adynamic bone disease: May develop with oversuppression of PTH; monitor bone-specific alkaline phosphatase.
Ventricular fibrillation, digitalis toxicity, hypersensitivity, AV block (unless pacemaker present), Wolff-Parkinson-White syndrome.
Hypocalcemia,Known hypersensitivity to cinacalcet or any component of the formulation
Avoid licorice, which can cause hypokalemia. Maintain consistent intake of potassium-rich foods (bananas, oranges) to avoid fluctuations. No known significant food interactions beyond electrolyte effects.
Take with food or immediately after a dialysis treatment. Avoid high-calcium meals (e.g., dairy) within 2 hours of dosing as calcium binds cinacalcet and reduces absorption. No other dietary restrictions; maintain consistent calcium intake per renal diet.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avoids if possible.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cinacalcet produced fetal toxicity (reduced fetal weight, increased incidence of skeletal variations) at doses 0.5-4 times the maximum human dose. Risk cannot be ruled out. Use only if potential benefit justifies potential risk to fetus.
Deslanoside is excreted in breast milk; estimated infant dose 0.1-0.5% of maternal weight-adjusted dose; M/P ratio not well defined. Monitor infant for bradycardia, feeding difficulties; benefit likely outweighs risk.
No data on presence in human milk. In lactating rats, cinacalcet was excreted in milk with milk:plasma ratio approximately 2.4. Potential for serious adverse reactions in nursing infants; decision to discontinue nursing or drug should consider importance of drug to mother.
Increased renal clearance in pregnancy may require higher doses; monitor serum drug levels and adjust accordingly. Reduced dosing in third trimester may be needed due to volume expansion.
No specific dosing adjustments are established due to lack of pharmacokinetic data in pregnancy. Serum calcium and PTH should be monitored frequently to guide dosing, as volume distribution and clearance may change. Generally, maintain lowest effective dose to control hyperparathyroidism.
Cedilanid-D (deslanoside) is a rapidly acting parenteral digitalis glycoside. Use with extreme caution in renal impairment due to reduced clearance. Monitor serum potassium and magnesium; hypokalemia and hypomagnesemia potentiate toxicity. Administer slow IV push over 5 minutes to avoid arrhythmias. Therapeutic drug monitoring less common due to short half-life of 33 hours. Contraindicated in ventricular tachycardia and AV block (unless due to atrial fibrillation).
Monitor serum calcium within 1 week of initiation or dose adjustment; cinacalcet may cause hypocalcemia, so do not start if calcium <8.4 mg/d L. Correct elevated PTH in CKD patients with i PTH >300 pg/m L on dialysis; not for use in non-dialysis CKD. QTc prolongation risk: obtain baseline ECG and monitor electrolytes, especially if on QT-prolonging drugs. Nausea and vomiting are common; administer with food or after dialysis session to improve tolerance.
Take exactly as prescribed; do not double doses.,Report symptoms of toxicity: nausea, vomiting, visual disturbances (yellow-green halos), irregular heartbeat.,Avoid over-the-counter medications without consulting doctor.,Maintain consistent potassium intake; avoid high-potassium foods or supplements unless advised.,Monitor daily weight and report rapid weight gain or edema.
Take cinacalcet with food or right after a dialysis session to reduce stomach upset.,Do not stop taking this medication suddenly; consult your doctor if you have side effects.,Report symptoms of low calcium such as muscle cramps, numbness, or tingling in fingers/toes.,Tell your doctor if you have a history of seizures or liver problems.,Avoid taking strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) unless prescribed; inform all healthcare providers.
No interactions on record
"Cinacalcet, a potent CYP3A4 inhibitor, significantly decreases the metabolism of Indinavir, a CYP3A4 substrate. This leads to elevated plasma concentrations of Indinavir, increasing the risk of dose-related toxicities such as nephrolithiasis, acute interstitial nephritis, and hepatotoxicity. The interaction may require Indinavir dose reduction and close monitoring for adverse effects."
"Duloxetine, a moderate inhibitor of CYP2D6 and CYP1A2, can reduce the metabolism of cinacalcet, a CYP2D6 and CYP1A2 substrate, leading to increased plasma concentrations of cinacalcet. This elevation may enhance the pharmacodynamic effects of cinacalcet, including a greater reduction in parathyroid hormone (PTH) and increased risk of hypocalcemia. Clinically, patients may experience symptoms such as paresthesias, muscle cramps, or cardiac arrhythmias due to electrolyte disturbances."
"Nitrofural, an antibacterial agent, is a potent inhibitor of CYP450 enzymes, particularly CYP3A4 and CYP1A2. Cinacalcet is extensively metabolized by CYP3A4 and, to a lesser extent, CYP1A2. Concomitant use of Nitrofural with Cinacalcet significantly reduces the systemic clearance of Cinacalcet, leading to elevated plasma concentrations. This increases the risk of dose-dependent adverse effects such as hypocalcemia, QT prolongation, and seizures."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEDILANID-D vs CINACALCET HYDROCHLORIDE, answered by our medical review team.
CEDILANID-D is a Cardiac Glycoside that works by Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.. CINACALCET HYDROCHLORIDE is a Calcimimetic that works by Allosteric activator of the calcium-sensing receptor (Ca SR) on parathyroid chief cells, increasing sensitivity to extracellular calcium and reducing parathyroid hormone (PTH) secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEDILANID-D and CINACALCET HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEDILANID-D is: 0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.. The standard adult dose of CINACALCET HYDROCHLORIDE is: 30 mg orally once daily, titrate every 2-4 weeks to a maximum of 180 mg once daily to achieve target intact parathyroid hormone (i PTH) level.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CEDILANID-D and CINACALCET HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CEDILANID-D is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avo. CINACALCET HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cinacalcet produced fetal toxicity (reduced fetal weight, increased incidence of skeletal variat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.